Ignite Creation Date:
2024-05-06 @ 7:04 AM
Last Modification Date:
2024-10-26 @ 11:44 AM
Study NCT ID:
NCT02465528
Status:
TERMINATED
Last Update Posted:
2019-12-27
First Post:
2015-05-29
Brief Title:
Ceritinib Rare Indications Study in ALK Tumors
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Glioblastoma |
| Tumors With Aberrations in ALK |
| Anaplastic Large Cell Lymphoma |
| Inflammatory Myofibroblastic Tumor |